James R Eshleman

List of Publications by Year
in descending order

121 papers	34,560 citations	47 h-index	118 g-index
		47006	19190
123 all docs	123 docs citations	123 times ranked	38001 citing authors

#	Article	IF	Citations
1	Validation of Long Mononucleotide Repeat Markers for Detection of Microsatellite Instability. Journal of Molecular Diagnostics, 2022, 24, 144-157.	2.8	10
2	Functional CDKN2A assay identifies frequent deleterious alleles misclassified as variants of uncertain significance. ELife, 2022, 11, .	6.0	6
3	Utility of targeted next-generation sequencing assay to detect 1p/19q co-deletion in formalin-fixed paraffin-embedded glioma specimens. Human Pathology, 2022, 126, 63-76.	2.0	5
4	PINâ€like ductal carcinoma of the prostate has frequent activating RAS/RAF mutations. Histopathology, 2021, 78, 327-333.	2.9	9
5	Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer. Oncologist, 2021, 26, e270-e278.	3.7	33
6	Nivolumab plus ipilimumab, with or without enzalutamide, in ARâ€V7â€expressing metastatic castrationâ€resistant prostate cancer: A phaseâ€2 nonrandomized clinical trial. Prostate, 2021, 81, 326-338.	2.3	35
7	Val16A SOD2 Polymorphism Promotes Epithelialâ€“Mesenchymal Transition Antagonized by Muscadine Grape Skin Extract in Prostate Cancer Cells. Antioxidants, 2021, 10, 213.	5.1	2
8	Pancreatic cancer pathology viewed in the light of evolution. Cancer and Metastasis Reviews, 2021, 40, 661-674.	5.9	7
9	Heat Shock Protein 90 Inhibitor Effects on Pancreatic Cancer Cell Cultures. Pancreas, 2021, 50, 625-632.	1.1	2
10	IDH1 and IDH2 Mutations in Colorectal Cancers. American Journal of Clinical Pathology, 2021, 156, 777-786.	0.7	12
11	Double PIK3CA Alterations and Parallel Evolution in Colorectal Cancers. American Journal of Clinical Pathology, 2021, , .	0.7	0
12	CloneRetriever: An Automated Algorithm to Identify Clonal B and T Cell Gene Rearrangements by Next-Generation Sequencing for the Diagnosis of Lymphoid Malignancies. Clinical Chemistry, 2021, 67, 1524-1533.	3.2	1
13	A Cost-Effective and Non-Invasive pfeRNA-Based Test Differentiates Benign and Suspicious Pulmonary Nodules from Malignant Ones. Non-coding RNA, 2021, 7, 80.	2.6	2
14	Gene Variants That Affect Levels of Circulating Tumor Markers Increase Identification of Patients With Pancreatic Cancer. Clinical Gastroenterology and Hepatology, 2020, 18, 1161-1169.e5.	4.4	31
15	Comprehensive mutagenesis on yeast cytosine deaminase yields improvements in 5â€fluorocytosine toxicity in HT1080 cells. AICHE Journal, 2020, 66, e16688.	3.6	3
16	Tetraploid Partial Hydatidiform Moles. Journal of Molecular Diagnostics, 2020, 22, 90-100.	2.8	12
17	Successful gene therapy requires targeting the vast majority of cancer cells. Cancer Biology and Therapy, 2020, 21, 946-953.	3.4	1
18	Molecular characterization of organoids derived from pancreatic intraductal papillary mucinous neoplasms. Journal of Pathology, 2020, 252, 252-262.	4.5	30

#	Article	IF	Citations
19	The genetics of ductal adenocarcinoma of the pancreas in the year 2020: dramatic progress, but far to go. Modern Pathology, 2020, 33, 2544-2563.	5.5	23
20	Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer. Annals of Surgery, 2020, 272, 427-435.	4.2	61
21	Clonal Origin Evaluated by Trunk and Branching Drivers and Prevalence of Mutations in Multiple Lung Tumor Nodules. Molecular Diagnosis and Therapy, 2020, 24, 461-472.	3.8	3
22	HIST1H2BB and MAGI2 Methylation and Somatic Mutations as Precision Medicine Biomarkers for Diagnosis and Prognosis of High-grade Serous Ovarian Cancer. Cancer Prevention Research, 2020, 13, 783-794.	1.5	11
23	Detection of Circulating Tumor DNA in Patients with Pancreatic Cancer Using Digital Next-Generation Sequencing. Journal of Molecular Diagnostics, 2020, 22, 748-756.	2.8	11
24	IDH1 and IDH2 mutations in lung adenocarcinomas: Evidences of subclonal evolution. Cancer Medicine, 2020, 9, 4386-4394.	2.8	18
25	Multiclonal colorectal cancers with divergent histomorphological features and RAS mutations: one cancer or separate cancers?. Human Pathology, 2020, 98, 120-128.	2.0	4
26	Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing. BMC Cancer, 2019, 19, 665.	2.6	42
27	A pilot study of prostateâ€specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer. Prostate, 2019, 79, 1597-1603.	2.3	18
28	Axon Guidance Molecules Promote Perineural Invasion and Metastasis of Orthotopic Pancreatic Tumors in Mice. Gastroenterology, 2019, 157, 838-850.e6.	1.3	88
29	Clinical Validation of Discordant Trunk Driver Mutations in Paired Primary and Metastatic Lung Cancer Specimens. American Journal of Clinical Pathology, 2019, 152, 570-581.	0.7	6
30	Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer. Clinical Cancer Research, 2019, 25, 4973-4984.	7.0	118
31	A New Fast Phasing Method Based On Haplotype Subtraction. Journal of Molecular Diagnostics, 2019, 21, 427-436.	2.8	1
32	JAK3 Variant, Immune Signatures, DNA Methylation, and Social Determinants Linked to Survival Racial Disparities in Head and Neck Cancer Patients. Cancer Prevention Research, 2019, 12, 255-270.	1.5	19
33	Prediction of Recurrence With KRAS Mutational Burden Using Ultrasensitive Digital Polymerase Chain Reaction of Radial Resection Margin of Resected Pancreatic Ductal Adenocarcinoma. Pancreas, 2019, 48, 400-411.	1.1	2
34	Biphenotypic Differentiation of Pancreatic Cancer in 3-Dimensional Culture. Pancreas, 2019, 48, 1225-1231.	1.1	2
35	Clinical Validation of Coexisting Activating Mutations Within EGFR, Mitogen-Activated Protein Kinase, and Phosphatidylinositol 3-Kinase Pathways in Lung Cancers. Archives of Pathology and Laboratory Medicine, 2019, 143, 174-182.	2.5	15
36	Clinical validation of coexisting driver mutations in colorectal cancers. Human Pathology, 2019, 86, 12-20.	2.0	10

#	Article	IF	Citations
37	Mutations in the pancreatic secretory enzymes CPA1 and CPB1 are associated with pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 4767-4772.	7.1	65
38	Simple Detection of Telomere Fusions in Pancreatic Cancer, Intraductal Papillary Mucinous Neoplasm, and Pancreatic Cyst Fluid. Journal of Molecular Diagnostics, 2018, 20, 46-55.	2.8	16
39	Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer. Oncotarget, 2018, 9, 28561-28571.	1.8	129
40	Endocrine mucinâ€producing sweat gland carcinoma: A study of 11 cases with molecular analysis. Journal of Cutaneous Pathology, 2018, 45, 681-687.	1.3	28
41	Validation Strategy for Ultrasensitive Mutation Detection. Molecular Diagnosis and Therapy, 2018, 22, 603-611.	3.8	0
42	Alterations of type II classical cadherin, cadherinâ€10 (CDH10), is associated with pancreatic ductal adenocarcinomas. Genes Chromosomes and Cancer, 2017, 56, 427-435.	2.8	8
43	Patients with McCune-Albright syndrome have a broad spectrum of abnormalities in the gastrointestinal tract and pancreas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 391-400.	2.8	39
44	Haplotype Counting for Sensitive Chimerism Testing. Journal of Molecular Diagnostics, 2017, 19, 427-436.	2.8	10
45	Susceptibility of ATM-deficient pancreatic cancer cells to radiation. Cell Cycle, 2017, 16, 991-998.	2.6	24
46	Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science, 2017, 357, 409-413.	12.6	4,945
47	Analytical Validation of Androgen Receptor Splice Variant 7 Detection in a Clinical Laboratory Improvement Amendments (CLIA) Laboratory Setting. Journal of Molecular Diagnostics, 2017, 19, 115-125.	2.8	41
48	MSH2 Loss in Primary Prostate Cancer. Clinical Cancer Research, 2017, 23, 6863-6874.	7.0	122
49	Morphology and genetics of pyloric gland adenomas in familial adenomatous polyposis. Histopathology, 2017, 70, 549-557.	2.9	20
50	Hypermutation In Pancreatic Cancer. Gastroenterology, 2017, 152, 68-74.e2.	1.3	174
51	Clinical Utility of CLIA-Grade AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer. JCO Precision Oncology, 2017, 2017, 1-9.	3.0	42
52	Phase 2 biomarker-driven study of ipilimumab plus nivolumab (Ipi/Nivo) for ARV7-positive metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2017, 35, 5035-5035.	1.6	19
53	Clinical utility of CLIA-grade AR-V7 testing in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2017, 35, 183-183.	1.6	1
54	Clinical mutational profiling of 1006 lung cancers by next generation sequencing. Oncotarget, 2017, 8, 96684-96696.	1.8	32

#	Article	IF	Citations
55	Heterogeneity of resistance mutations detectable by next-generation sequencing in TKI-treated lung adenocarcinoma. Oncotarget, 2016, 7, 45237-45248.	1.8	25
56	Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective. BioMed Research International, 2016, 2016, 1-12.	1.9	19
57	Clinical mutational profiling of bone metastases of lung and colon carcinoma and malignant melanoma using nextâ€generation sequencing. Cancer Cytopathology, 2016, 124, 744-753.	2.4	31
58	Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide. Prostate, 2016, 76, 1484-1490.	2.3	29
59	Test Feasibility of Next-Generation Sequencing Assays in Clinical Mutation Detection of Small Biopsy and Fine Needle Aspiration Specimens. American Journal of Clinical Pathology, 2016, 145, 696-702.	0.7	22
60	Nanopore sequencing detects structural variants in cancer. Cancer Biology and Therapy, 2016, 17, 246-253.	3.4	130
61	Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer. Cancer Discovery, 2016, 6, 166-175.	9.4	282
62	Microsatellite Instability as a Biomarker for PD-1 Blockade. Clinical Cancer Research, 2016, 22, 813-820.	7.0	698
63	Association of BRAF^{V600E} Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers. Thyroid, 2016, 26, 532-542.	4.5	50
64	Genomic analyses identify molecular subtypes of pancreatic cancer. Nature, 2016, 531, 47-52.	27.8	2,700
65	Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation. Leukemia, 2016, 30, 1916-1920.	7.2	79
66	Programmed death-1 blockade in mismatch repair deficient colorectal cancer.. Journal of Clinical Oncology, 2016, 34, 103-103.	1.6	50
67	PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers.. Journal of Clinical Oncology, 2016, 34, 195-195.	1.6	39
68	Cost-benefit analysis of AR-V7 testing in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) eligible for abiraterone (Abi) or enzalutamide (Enza).. Journal of Clinical Oncology, 2016, 34, 283-283.	1.6	0
69	Transflip mutations produce deletions in pancreatic cancer. Genes Chromosomes and Cancer, 2015, 54, 472-481.	2.8	9
70	Clinical detection and categorization of uncommon and concomitant mutations involving BRAF. BMC Cancer, 2015, 15, 779.	2.6	92
71	PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. New England Journal of Medicine, 2015, 372, 2509-2520.	27.0	7,696
72	Familial and sporadic pancreatic cancer share the same molecular pathogenesis. Familial Cancer, 2015, 14, 95-103.	1.9	54

#	Article	IF	Citations
73	Whole genomes redefine the mutational landscape of pancreatic cancer. Nature, 2015, 518, 495-501.	27.8	2,132
74	Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers. Modern Pathology, 2015, 28, 1390-1399.	5.5	53
75	Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nature Communications, 2015, 6, 7686.	12.8	393
76	KRAS and Guanine Nucleotide-Binding Protein Mutations in Pancreatic Juice Collected From the Duodenum of Patients at High Risk for Neoplasia Undergoing Endoscopic Ultrasound. Clinical Gastroenterology and Hepatology, 2015, 13, 963-969.e4.	4.4	74
77	Non-p.V600E BRAF Mutations Are Common Using a More Sensitive and Broad Detection Tool. American Journal of Clinical Pathology, 2015, 144, 620-628.	0.7	43
78	Lymph node metastases of melanoma: challenges for BRAF mutation detection. Human Pathology, 2015, 46, 113-119.	2.0	16
79	PD-1 blockade in tumors with mismatch repair deficiency.. Journal of Clinical Oncology, 2015, 33, LBA100-LBA100.	1.6	22
80	PD-1 blockade in tumors with mismatch repair deficiency.. Journal of Clinical Oncology, 2015, 33, LBA100-LBA100.	1.6	31
81	Mutational profiling of colorectal cancers with microsatellite instability. Oncotarget, 2015, 6, 42334-42344.	1.8	69
82	Advancements in the Development of HIF-1Î±-Activated Protein Switches for Use in Enzyme Prodrug Therapy. PLoS ONE, 2014, 9, e114032.	2.5	9
83	Cytosine Deamination Is a Major Cause of Baseline Noise in Next-Generation Sequencing. Molecular Diagnosis and Therapy, 2014, 18, 587-593.	3.8	129
84	Wholeâ€exome sequencing of pancreatic neoplasms with acinar differentiation. Journal of Pathology, 2014, 232, 428-435.	4.5	151
85	Tumor Cellularity as a Quality Assurance Measure for Accurate Clinical Detection of BRAF Mutations in Melanoma. Molecular Diagnosis and Therapy, 2014, 18, 409-418.	3.8	34
86	Clinical Validation of KRAS, BRAF, and EGFR Mutation Detection Using Next-Generation Sequencing. American Journal of Clinical Pathology, 2014, 141, 856-866.	0.7	128
87	Improved FLT3 Internal Tandem Duplication PCR Assay Predicts Outcome after Allogeneic Transplant for Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2014, 20, 1989-1995.	2.0	31
88	Haplotype Counting by Next-Generation Sequencing for Ultrasensitive Human DNA Detection. Journal of Molecular Diagnostics, 2014, 16, 495-503.	2.8	17
89	False Positives in Multiplex PCR-Based Next-Generation Sequencing Have Unique Signatures. Journal of Molecular Diagnostics, 2014, 16, 541-549.	2.8	43
90	DNA Mismatch Repair Defects and Microsatellite Instability Status in Periocular Sebaceous Carcinoma. American Journal of Ophthalmology, 2014, 157, 640-647.e2.	3.3	23

#	Article	IF	Citations
91	Clinicopathological Correlates of Activating GNAS Mutations in Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas. Annals of Surgical Oncology, 2013, 20, 3802-3808.	1.5	158
92	Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice. Clinical Cancer Research, 2013, 19, 1139-1146.	7.0	24
93	Tandem Duplication PCR. Diagnostic Molecular Pathology, 2013, 22, 149-155.	2.1	10
94	MutantGNASdetected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts. Gut, 2013, 62, 1024-1033.	12.1	160
95	ATM Mutations in Patients with Hereditary Pancreatic Cancer. Cancer Discovery, 2012, 2, 41-46.	9.4	442
96	Loss of expression of the SWI/SNF chromatin remodeling subunit BRG1/SMARCA4 is frequently observed in intraductal papillary mucinous neoplasms of the pancreas. Human Pathology, 2012, 43, 585-591.	2.0	56
97	Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature, 2012, 491, 399-405.	27.8	1,741
98	Î”-PCR, A Simple Method to Detect Translocations and Insertion/Deletion Mutations. Journal of Molecular Diagnostics, 2011, 13, 85-92.	2.8	17
99	Recurrent GNAS Mutations Define an Unexpected Pathway for Pancreatic Cyst Development. Science Translational Medicine, 2011, 3, 92ra66.	12.4	703
100	Analysis of Hematopoietic Stem Cell Transplant Engraftment. Diagnostic Molecular Pathology, 2011, 20, 194-202.	2.1	6
101	A protein therapeutic modality founded on molecular regulation. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 16206-16211.	7.1	41
102	Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 21188-21193.	7.1	585
103	Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature, 2010, 467, 1114-1117.	27.8	2,184
104	Verification and Unmasking of Widely Used Human Esophageal Adenocarcinoma Cell Lines. Journal of the National Cancer Institute, 2010, 102, 271-274.	6.3	116
105	Comparison of Sanger Sequencing, Pyrosequencing, and Melting Curve Analysis for the Detection of KRAS Mutations. Journal of Molecular Diagnostics, 2010, 12, 425-432.	2.8	422
106	Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene. Science, 2009, 324, 217-217.	12.6	713
107	Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses. Science, 2008, 321, 1801-1806.	12.6	3,755
108	Application of Traditional Clinical Pathology Quality Control Techniques to Molecular Pathology. Journal of Molecular Diagnostics, 2008, 10, 142-146.	2.8	17

#	Article	IF	Citations
109	Sensitive and quantitative detection of KRAS2 gene mutations in pancreatic duct juice differentiates patients with pancreatic cancer from chronic pancreatitis, potential for early detection. Cancer Biology and Therapy, 2008, 7, 353-360.	3.4	67
110	Genetic and Epigenetic Alterations of Familial Pancreatic Cancers. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 3536-3542.	2.5	79
111	Anti-gene padlocks eliminate Escherichia coli based on their genotype. Journal of Antimicrobial Chemotherapy, 2008, 61, 262-272.	3.0	4
112	Familial pancreatic cancer: from genes to improved patient care. Expert Review of Gastroenterology and Hepatology, 2007, 1, 81-88.	3.0	16
113	Evaluation of the Cepheid GeneXpert BCR-ABL Assay. Journal of Molecular Diagnostics, 2007, 9, 220-227.	2.8	44
114	Comparison of the Microsatellite Instability Analysis System and the Bethesda Panel for the Determination of Microsatellite Instability in Colorectal Cancers. Journal of Molecular Diagnostics, 2006, 8, 305-311.	2.8	234
115	LigAmp for sensitive detection of single-nucleotide differences. Nature Methods, 2004, 1, 141-147.	19.0	366
116	Conversion of diploidy to haploidy. Nature, 2000, 403, 723-724.	27.8	248
117	Use of Single Nucleotide Polymorphisms (SNP) and Real-Time Polymerase Chain Reaction for Bone Marrow Engraftment Analysis. Journal of Molecular Diagnostics, 2000, 2, 202-208.	2.8	58
118	Detection of Microsatellite Instability by Fluorescence Multiplex Polymerase Chain Reaction. Journal of Molecular Diagnostics, 2000, 2, 20-28.	2.8	133
119	Leukemia Arising out of Paroxysmal Nocturnal Hemoglobinuria. Leukemia and Lymphoma, 1999, 32, 401-426.	1.3	57
120	Chromosome number and structure both are markedly stable in RER colorectal cancers and are not destabilized by mutation of p53. Oncogene, 1998, 17, 719-725.	5.9	116
121	Mismatch repair defects in human carcinogenesis. Human Molecular Genetics, 1996, 5, 1489-1494.	2.9	217